Skip to main content
Luye Pharma Group Limited logo

Luye Pharma Group Limited — Investor Relations & Filings

Ticker · 2186 HKEX Manufacturing
Open in API
Filings indexed 1,503 across all filing types
Latest filing 2024-12-17 Report Publication Anno…
Country HK Hong Kong
Listing HKEX 2186

About Luye Pharma Group Limited

http://www.luye.cn

Luye Pharma Group is an international pharmaceutical company dedicated to the research, development, manufacturing, and commercialization of innovative medications, novel formulations, and biopharmaceutical products. The company's core strategy emphasizes advanced drug delivery systems, including microspheres, liposomes, and transdermal technologies, to enhance therapeutic efficacy and patient compliance. Luye Pharma maintains a strong focus on key therapeutic areas, particularly the Central Nervous System (CNS). Its portfolio includes proprietary products such as Roxinlin® (Toludesvenlafaxine extended-release tablets) and various long-acting injectable antipsychotic formulations, positioning the group as a global pharmaceutical enterprise.

Recent filings

Filing Released Lang Actions
Notification Letter and Reply Form to Registered Shareholders
Report Publication Announcement Classification · 85% confidence The document is a notification letter titled “Notice of publication of Interim Report 2024,” informing shareholders that the Company’s interim report is available on the website and outlining how to request printed copies or electronic delivery. It does not contain the interim financial report itself, but rather announces its publication and provides access instructions. This matches the definition of a Report Publication Announcement (RPA).
2024-12-17 English
Interim Report 2024
Interim / Quarterly Report Classification · 100% confidence The document is explicitly titled '2024 INTERIM REPORT' and contains comprehensive financial statements, including the 'Condensed Consolidated Statement of Profit or Loss', 'Condensed Consolidated Statement of Financial Position', and 'Management Discussion and Analysis' for the six months ended 30 September 2024. It meets the criteria for an Interim/Quarterly Report (IR) as it provides substantive financial data and analysis for a period shorter than a full fiscal year. H1 2024
2024-12-17 English
OVERSEAS REGULATORY ANNOUNCEMENT
Capital/Financing Update Classification · 88% confidence The document is an overseas regulatory announcement by Luye Pharma regarding the issue of US$50,000,000 5.85% convertible bonds due 2025 and the publication of the related information memorandum to comply with HKEX Listing Rule 13.10B. This is not a full report but an announcement of a financing transaction and the dissemination of the information memorandum. It clearly relates to the company’s fundraising and capital structure. Therefore, it best fits the “Capital/Financing Update” category (CAP).
2024-12-16 English
COMPLETION OF THE ISSUE OF US$50,000,000 5.85 PER CENT. CONVERTIBLE BONDS DUE 2025
Capital/Financing Update Classification · 90% confidence The document is an announcement by Luye Pharma Group Ltd. regarding the completion of its US$50 million 5.85% convertible bonds issuance and listing. This is a financing activity update—specifically a capital raising via convertible bonds—so it fits the 'Capital/Financing Update (CAP)' category rather than a share issue (SHA) or a report publication.
2024-12-13 English
CHANGE OF PRINCIPAL SHARE REGISTRAR AND TRANSFER AGENT IN BERMUDA
Regulatory Filings Classification · 85% confidence The document is a stock exchange announcement regarding the change of the company’s principal share registrar and transfer agent in Bermuda. It does not involve financial results, share issuance, dividends, M&A, management changes, or other specific reporting categories. It’s a general regulatory announcement, so it falls into the fallback “Regulatory Filings” category (RNS).
2024-12-09 English
Monthly Return of Equity Issuer on Movements in Securities
Regulatory Filings Classification · 85% confidence The document is a completed FF301 form submitted to the Hong Kong Stock Exchange as the Monthly Return for Equity Issuers and Hong Kong Depositary Receipts under Chapter 19B of the Listing Rules. It details movements in authorised share capital, issued shares, treasury shares, and share option schemes for the month-ended period. There is no indication of an earnings announcement, management discussion, capital raising notice, proxy materials, or dividend declaration. This is a routine regulatory submission for share movements and thus best fits the fallback category of general regulatory filings (RNS).
2024-12-04 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.